Q2 EPS Forecast for Neurocrine Biosciences Lifted by Analyst

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – William Blair lifted their Q2 2025 earnings estimates for Neurocrine Biosciences in a research note issued on Tuesday, May 6th. William Blair analyst M. Minter now expects that the company will earn $1.02 per share for the quarter, up from their previous forecast of $0.85. William Blair has a “Outperform” rating on the stock. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $4.28 per share. William Blair also issued estimates for Neurocrine Biosciences’ Q3 2025 earnings at $1.25 EPS, Q4 2025 earnings at $1.36 EPS, Q1 2026 earnings at $1.66 EPS, Q2 2026 earnings at $1.85 EPS, Q3 2026 earnings at $1.80 EPS, Q4 2026 earnings at $2.25 EPS and FY2026 earnings at $7.56 EPS.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Monday, May 5th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by ($0.62). The firm had revenue of $572.60 million for the quarter, compared to analyst estimates of $587.06 million. Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%. The business’s revenue was up 11.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.20 EPS.

Several other analysts also recently weighed in on NBIX. Guggenheim upped their price objective on Neurocrine Biosciences from $155.00 to $165.00 and gave the stock a “buy” rating in a research report on Tuesday, May 6th. Needham & Company LLC raised their price target on shares of Neurocrine Biosciences from $138.00 to $139.00 and gave the company a “buy” rating in a research note on Tuesday, May 6th. UBS Group upped their price objective on shares of Neurocrine Biosciences from $137.00 to $152.00 and gave the stock a “buy” rating in a research report on Tuesday, May 6th. Wedbush restated an “outperform” rating on shares of Neurocrine Biosciences in a research report on Tuesday, May 6th. Finally, Piper Sandler reiterated an “overweight” rating and set a $154.00 price target (down from $160.00) on shares of Neurocrine Biosciences in a report on Tuesday, May 6th. Three analysts have rated the stock with a hold rating and twenty have issued a buy rating to the stock. Based on data from MarketBeat, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $162.00.

Neurocrine Biosciences Price Performance

NASDAQ NBIX opened at $115.71 on Friday. The business has a fifty day moving average price of $106.23 and a two-hundred day moving average price of $121.85. The stock has a market capitalization of $11.45 billion, a PE ratio of 35.17, a PEG ratio of 0.77 and a beta of 0.26. Neurocrine Biosciences has a fifty-two week low of $84.23 and a fifty-two week high of $157.98.

Neurocrine Biosciences announced that its Board of Directors has initiated a stock buyback plan on Friday, February 21st that permits the company to repurchase $500.00 million in outstanding shares. This repurchase authorization permits the company to purchase up to 4.2% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s board of directors believes its stock is undervalued.

Insider Buying and Selling

In related news, insider Julie Cooke sold 700 shares of the firm’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $118.28, for a total transaction of $82,796.00. Following the transaction, the insider now directly owns 18,831 shares of the company’s stock, valued at $2,227,330.68. This trade represents a 3.58 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director William H. Rastetter sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $110.20, for a total value of $3,306,000.00. Following the completion of the transaction, the director now owns 37,491 shares in the company, valued at $4,131,508.20. The trade was a 44.45 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 43,907 shares of company stock valued at $4,935,982. 4.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in shares of Neurocrine Biosciences by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 10,119,641 shares of the company’s stock worth $1,381,331,000 after buying an additional 122,681 shares during the last quarter. Dodge & Cox increased its stake in shares of Neurocrine Biosciences by 134.2% during the 4th quarter. Dodge & Cox now owns 3,016,425 shares of the company’s stock worth $411,742,000 after purchasing an additional 1,728,605 shares during the last quarter. AQR Capital Management LLC raised its holdings in shares of Neurocrine Biosciences by 2.9% in the 4th quarter. AQR Capital Management LLC now owns 1,896,891 shares of the company’s stock worth $258,926,000 after purchasing an additional 53,610 shares during the period. Geode Capital Management LLC lifted its stake in Neurocrine Biosciences by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 1,875,062 shares of the company’s stock valued at $255,523,000 after purchasing an additional 15,830 shares during the last quarter. Finally, Wellington Management Group LLP grew its holdings in Neurocrine Biosciences by 102.9% during the fourth quarter. Wellington Management Group LLP now owns 1,457,425 shares of the company’s stock valued at $198,939,000 after purchasing an additional 739,199 shares during the period. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.